Literature DB >> 18413769

Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.

Claire N Janicki1, S Rhiannon Jenkinson, Neil A Williams, David J Morgan.   

Abstract

A major problem in generating effective antitumor CTL responses is that most tumors express self-antigens to which the immune system is rendered unresponsive due to mechanisms of self-tolerance induction. CTL precursors (CTLp) expressing high-affinity T-cell receptors (TCR) are often functionally deleted from the repertoire, leaving a residual repertoire of CTLp having only low-affinity TCR. Furthermore, even when unique antigens are expressed, their presentation by dendritic cells (DC) may predispose to peripheral tolerance induction rather than the establishment of CTL responses that kill tumor cells. In this study, we examined both high-avidity (CL4) and low-avidity (CL1) CD8(+) T-cell responses to a murine renal carcinoma expressing, as a neoantigen, high and low levels of the hemagglutinin (HA) protein from influenza virus A/PR/8 H1N1 (PR8; RencaHA(high) and RencaHA(low)). Our data show that, following encounter with K(d)HA epitopes cross-presented by bone marrow-derived DC, low-avidity CL1 cells become tolerized within tumor-draining lymph nodes (TDLN), and in mice bearing either RencaHA(high) or RencaHA(low) tumors, very few form tumor-infiltrating lymphocytes (TIL). In marked contrast, high-avidity CL4 cells differentiate into effector CTL within the TDLN of mice bearing either RencaHA(high) or RencaHA(low) tumors, and although they form TIL in both tumors, they lose CTL effector function. Critically, these results show that anticancer therapies involving either adoptive transfer of high-avidity tumor-specific CTL populations or targeting of preexisting tumor antigen-specific memory CD8(+) T cells could fail due to the fact that CTL effector function is lost following tumor infiltration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18413769     DOI: 10.1158/0008-5472.CAN-07-5008

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

1.  Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8+ T Cells.

Authors:  Christopher D Zahm; Viswa T Colluru; Douglas G McNeel
Journal:  Cancer Immunol Res       Date:  2017-06-20       Impact factor: 11.151

2.  T cell avidity and tumor immunity: problems and solutions.

Authors:  Arthur A Hurwitz; Steven M Cuss; Katherine E Stagliano; Ziqiang Zhu
Journal:  Cancer Microenviron       Date:  2013-12-20

3.  Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity.

Authors:  Stephanie K Dougan; Michael Dougan; Jun Kim; Jacob A Turner; Souichi Ogata; Hyun-Il Cho; Rudolf Jaenisch; Esteban Celis; Hidde L Ploegh
Journal:  Cancer Immunol Res       Date:  2013-08       Impact factor: 11.151

4.  Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3.

Authors:  Jason Brayer; Fengdong Cheng; Hongwei Wang; Pedro Horna; Ildefonso Vicente-Suarez; Javier Pinilla-Ibarz; Eduardo M Sotomayor
Journal:  Immunol Lett       Date:  2010-03-25       Impact factor: 3.685

5.  Adoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escape.

Authors:  Karen M Kaluza; Timothy Kottke; Rosa Maria Diaz; Diana Rommelfanger; Jill Thompson; Richard Vile
Journal:  Hum Gene Ther       Date:  2012-08-13       Impact factor: 5.695

6.  Human renal cell carcinoma induces a dendritic cell subset that uses T-cell crosstalk for tumor-permissive milieu alterations.

Authors:  Ainhoa-M Figel; Dorothee Brech; Petra U Prinz; Ulrike K Lettenmeyer; Judith Eckl; Adriana Turqueti-Neves; Josef Mysliwietz; David Anz; Nicole Rieth; Niklas Muenchmeier; Alexander Buchner; Stefan Porubsky; Sabine I Siegert; Stephan Segerer; Peter J Nelson; Elfriede Noessner
Journal:  Am J Pathol       Date:  2011-05-18       Impact factor: 4.307

Review 7.  To affinity and beyond: harnessing the T cell receptor for cancer immunotherapy.

Authors:  Jessica E Thaxton; Zihai Li
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 8.  Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma.

Authors:  Christiane Geiger; Elfriede Nössner; Bernhard Frankenberger; Christine S Falk; Heike Pohla; Dolores J Schendel
Journal:  J Mol Med (Berl)       Date:  2009-03-07       Impact factor: 4.599

9.  High-avidity T cells are preferentially tolerized in the tumor microenvironment.

Authors:  Ziqiang Zhu; Vinod Singh; Stephanie K Watkins; Vincenzo Bronte; Jennifer L Shoe; Lionel Feigenbaum; Arthur A Hurwitz
Journal:  Cancer Res       Date:  2012-11-30       Impact factor: 12.701

Review 10.  Immunotherapy of human cancers using gene modified T lymphocytes.

Authors:  Juan F Vera; Malcolm K Brenner; Gianpietro Dotti
Journal:  Curr Gene Ther       Date:  2009-10       Impact factor: 4.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.